Progression-Free Survival Is Good Endpoint For Metastatic NSCLC, Cmte. Says
Executive Summary
An endpoint of progression-free survival is appropriate for full approval of first-line non-small cell lung cancer treatments in metastatic cancers, but not for earlier-stage disease, the Oncologic Drugs Advisory Committee concluded Dec. 16
You may also be interested in...
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.
FDA’s NSCLC Guidance Stresses Overall Survival Endpoint, Sets PFS Standards
FDA is using its new draft guidance on non-small cell lung cancer to once again stress the importance of using overall survival to prove efficacy and make clear that if progression-free survival measure is used, a “substantial and robust” effect should be shown.
Magnitude Of Effect, Not Survival, Is Key To Approval For Oncologic Nexavar
Sponsors of oncology agents should select endpoints where a drug is likely to have a "magnitude of effect" instead of focusing on survival, FDA said following its Dec. 20 approval of Bayer/Onyx' kidney cancer therapy Nexavar (sorafenib)